US2001006975A1PendingUtilityA1

Raf kinase inhibitors

47
Assignee: BAYER CORP AND ONYX PHARMACEUTPriority: May 23, 1997Filed: Jan 8, 2001Published: Jul 5, 2001
Est. expiryMay 23, 2017(expired)· nominal 20-yr term from priority
Inventors:Jill WoodHanno WildDaniel RogersJohn Francis LyonsMichael KatzYolanda CaringalRobert DallyWendy LeeRoger SmithCheri Blum
C07D 471/04C07D 409/12A61P 35/00C07D 417/12C07D 207/34C07D 307/68C07D 333/38
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for the treatment of cancerous cell growth mediated by raf kinase, comprising administering a compound of the formulae:  
                   
     
     
         2 . A method according to    claim 1   , comprising administering a compound of the formulae  
                   
     
     
         3 . A method according to claim l, comprising administering a compound of the formulae  
                                     
     
     
         4 . A method according to    claim 1   , comprising administering a compound of formulae  
                   
     
     
         5 . A method according to    claim 1   , comprising administering a compound of formulae  
                   
     
     
         6 . A method according to    claim 1   , comprising administering a compound of formulae  
                   
     
     
         7 . A method according to    claim 1   , comprising administering a compound of formulae  
                   
     
     
         8 . A compound of the formulae  
                                                       
     
     
         9 . A compound according to    claim 8   , of the formulae  
                   
     
     
         10 . A compound according to    claim 8   , of the formulae  
                   
     
     
         11 . A compound according to    claim 8   , of the formulae  
                   
     
     
         12 . A compound according to    claim 8   , of the formulae  
                   
     
     
         13 . A compound according to    claim 8   , of the formulae  
                   
     
     
         14 . A compound according to    claim 8   , of the formulae  
                   
     
     
         15 . A pharmaceutical composition comprising a compound according to    claim 8    and a physiologically acceptable carrier.  
     
     
         16 . A pharmaceutical composition comprising a compound according to    claim 14    and a physiologically acceptable carrier.  
     
     
         17 . A pharmaceutical composition comprising a compound according to    claim 8    and a physiologically acceptable carrier, in sterile form.

Join the waitlist — get patent alerts

Track US2001006975A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.